Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Alaunos Therapeutics, Inc. Director's Dealing 2021

Feb 26, 2021

35407_dirs_2021-02-26_226d1847-a455-42ea-acc1-bb38f6c28ece.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ZIOPHARM ONCOLOGY INC (ZIOP)
CIK: 0001107421
Period of Report: 2021-02-17

Reporting Person: Cunningham Timothy M. (interim CFO)